Liver X Receptor α Is Involved in the Transcriptional Regulation of the 6-Phosphofructo-2-Kinase/Fructose-2, 6-Bisphosphatase Gene

Li-Feng Zhao,1 Yasumasa Iwasaki,2 Mitsuru Nishiyama,1 Takaumi Taguchi,1 Makoto Tsugita,1 Mizuho Okazaki,1 Shuichi Nakayama,1 Machiko Kambayashi,2 Shimpei Fujimoto,1 Koshi Hashimoto,3 Koji Murao,4 and Yoshio Terada1

The activity of 6-phosphofructo-1-kinase is strictly controlled by fructose-2,6-bisphosphate, the level of which is regulated by another enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK2/FBP2). PFK2/FBP2 is a bifunctional enzyme, having kinase and phosphatase activities, and regulates both glycolysis and gluconeogenesis. Here, we examined the hormonal regulation of the PFK2/FBP2 gene in vitro using the reporter assay, the electrophoretic mobility shift assay (EMSA), and the chromatin immunoprecipitation (ChIP) assay in HuH7 cells and also using the mouse liver in vivo. We found that the transcriptional activity of the PFK2/FBP2 gene was stimulated by insulin and inhibited by cAMP and glucocorticoid. Liver X receptor (LXR) α showed a potent and specific stimulatory effect on PFK2/FBP2 gene transcription. Deletion and mutagenesis analyses identified the LXR response element (LXRE) in the 5′-promoter region of the PFK2/FBP2 gene. Binding of LXRe was confirmed by the EMSA and ChIP assay. Endogenous PFK2/FBP2 mRNA in the mouse liver was increased in the fasting/refeeding state compared with the fasting state. Altogether, PFK2/FBP2 gene transcription is found to be regulated in a way that is more similar to other glycolytic enzyme genes than to gluconeogenic genes. Furthermore, our data strongly suggest that LXRe is one of the key regulators of PFK2/FBP2 gene transcription.

Reagents and plasmids. Insulin, decamethasone, and forskolin were obtained from Sigma (St. Louis, MO), and the specific liver X receptor (LXR) α agonist TO-901317 was from Calbiochem (San Diego, CA). The 5′-promoter regions of the human PFK2/FBP2 gene (−1,107−33 bp; +1 designates the transcription start site) and the human LXRe gene (−2101−77 bp) were cloned by PCR and incorporated into a pMal Luc luciferase reporter plasmid (PFK2/FBP2-Luc and LXRe-Luc, PFKFB2, PFKFB3, and PFKFB4) that are differentially expressed, among which PFKFB1 is the dominant isoform in the liver (5).

The kinase and phosphatase activities of the liver isoform of PFK2/FBP2 are regulated by phosphorylation/dephosphorylation at Ser-32 by protein kinase and phosphatase. Indeed, during the fed state, insulin and carbohydrate dephosphorylate PFK2/FBP2 in the liver, and this makes the enzyme kinase dominant. Subsequently, fructose-6-phosphate is converted to F2,6BP, which activates PFK1 and inhibits fructose-1,6-bisphosphatase and finally stimulates glycolysis (Fig. 1A). On the other hand, during the fasting state, glucagon phosphorylates PFK2/FBP2 via cAMP/protein kinase A and makes the enzyme phosphatase dominant. As a result, decreased F2,6BP activates fructose-1,6-bisphosphatase and inhibits PFK1 and finally stimulates gluconeogenesis. By this mechanism, glycolysis and gluconeogenesis do not occur simultaneously (4).

Glucose metabolism is regulated not only at the enzyme activity level but also at the gene expression level (6,7). In general, transcription of the glycolytic enzyme gene is stimulated by insulin/glucose, whereas that of the gluconeogenic enzyme gene is enhanced by glucagon/cAMP. Glucocorticoid also is involved in the regulation of a variety of glycolytic/gluconeogenic enzyme genes. In this context, it is interesting to note how the expression of the bifunctional PFK2/FBP2 gene is regulated by these hormones and factors mentioned above. Previous studies have shown that the amount of rat PFK2/FBP2 mRNA was increased by fasting/refeeding and by insulin in vivo (8), whereas the inhibitory effect of glucagon/cAMP was observed in adult rat hepatocytes in vitro (9). In addition, glucocorticoid increased PFK2/FBP2 mRNA in rat hepatoma cell lines (10,11). These findings suggest that hormones/factors involved in glucose metabolism have profound effects not only on PFK2/FBP2 activity but also on its mRNA expression. However, the molecular mechanism of PFK2/FBP2 gene expression is not yet characterized, and the transcription factor(s) involved is unidentified. Thus, in this study, we first examined the transcriptional regulation of the PFK2/FBP2 gene both in vitro and in vivo. We also tried to identify the transcription factor(s) and its cis-acting element(s) responsible for the hormonal/nutritional regulation of PFK2/FBP2 gene expression.

RESEARCH DESIGN AND METHODS

Copyright © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
was added directly into the culture medium, and the cells were incubated for
X (Mlx) (13) also were constructed by standard molecular cloning techniques.
In each experiment, cells were plated and cultured in 24-well
plates with 50% con
mids for the human glucocorticoid receptor, insulin receptor, LXR
–
endogenous expression of PFK1 (PFKL; liver type) and each isoform of PFK2/FBP2 mRNAs in HuH7 cells analyzed by RT-PCR.
respectively). A variety of deletion mutants of the PFK2/FBP2 promoter-reporter plasmids (~688–448, and ~282–33 bp), a heterologous promoter construct containing only the LXR response element (LXRE) 2 of the PFK2/FBP2 gene (~191/165 bp) and the thymidine kinase (TK) minimal promoter, and expression plas-
mids for the human glucocorticoid receptor, insulin receptor, LXRE, LR3, retinoid X receptor (RXRα, RXRβ, RXRγ, RXRβ/γ, RXRβ/α, RXRγ/α, RXRβ/γ/α, or RXRα/β/γ, RXRβ/γ/α, RXRγ/α, RXRβ/γ/α/γ) were obtained from a different
were maintained at 37°C in a humid atmosphere with 5% CO2.
Luciferase assay. The luciferase assay was performed as previously described
RT-PCR in vitro. Endogenous expression of PFK1 (PFK1, liver type) and each isoform of PFK2/FBP2 mRNAs in HuH7 cells was examined by RT-PCR analysis. One
mRNA. Total RNA was extracted using the RNeasy RNA extraction kit
Luciferase activity was measured using the Dual-Glo Luciferase Assay System (Promega). Binding reactions contained 20 mmol/L HEPES (pH 7.6),
lysines. The probes used are shown in Fig. 6
was stained with Coomassie Blue, and the band intensities were determined using a gel documentation system (GelDoc XR; Bio-Rad, Hercules, CA).
The coexpression of various transcription factors on the putative
on the putative LXRE identified.
Chromatin immunoprecipitation assay. Chromatin immunoprecipitation
mRNA. In all experiments, the band intensities were determined from the
ChIP) assay was carried out using the ChIP-IT Express chromatin immu-
the binding of LXR to the LXR binding sites. The probes used are shown in Fig. 6
light output was measured for 20 s at room temperature using a
mRNA. M, molecular size marker (100-bp ladder). (A high-quality color
Electromobility shift assay (EMSA) analysis was

FIG. 1. A: Schematic representation of the role of PFK2/FBP2 in the F2,6P-mediated regulation of PFK1 in the glycolytic pathway in the liver. G6Pase, glucose-6-phosphatase; TCA, tricarboxylic acid cycle; GK, glucoki-
nase; G6Pase, glucose-6-phosphatase; F6P, fructose-6-phosphate; F2,6P, fructose-2,6-bisphosphatase; PPeA, protein phosphatase. B: Endogenous expression of PFK1 (PFKL; liver type) and each isoform of PFK2/FBP2 (PFKFB1 through PFKFB4) mRNAs in HuH7 cells analyzed by RT-PCR. The figure shows photographs of the ethidium bromide–stained products using agarose gel electrophoresis. Complementary DNA produced from the reverse transcriptase reaction, using total RNA from the cells, was amplified by PCR with pairs of oligonucleotide primers specific for each mRNA. M, molecular size marker (100-bp ladder). (A high-quality color representation of this figure is available in the online issue.)

To see the effects of the hormones involved in glucose metabolism on PFK2/
FBP2 gene 5′-promoter activity, each factor/reagent, in 1,000× concentration, was added directly into the culture medium, and the cells were incubated for
Dexamethasone was used to see the effect of pure glu-
ducted the formation of promoter activity.
To see the effects of the coexpression of various transcription factors on
the liver in vivo was examined by quantitative real-time PCR analysis. C57/BL6 mice
mouse PFK2/FBP2 mRNA (Applied Biosystems), and those
was harvested 24–48 h after the end of transfection, followed by the
cells were harvested 24–48 h after the end of transfection, followed by the
tivity of the band identi

To see the effects of the hormones involved in glucose metabolism on PFK2/
FBP2 gene 5′-promoter activity, each factor/reagent, in 1,000× concentration, was added directly into the culture medium, and the cells were incubated for
Dexamethasone was used to see the effect of pure glu-
ducted the formation of promoter activity.
To see the effects of the coexpression of various transcription factors on
the liver in vivo was examined by quantitative real-time PCR analysis. C57/BL6 mice
mouse PFK2/FBP2 mRNA (Applied Biosystems), and those
was harvested 24–48 h after the end of transfection, followed by the
cells were harvested 24–48 h after the end of transfection, followed by the
tivity of the band identi

To see the effects of the hormones involved in glucose metabolism on PFK2/
FBP2 gene 5′-promoter activity, each factor/reagent, in 1,000× concentration, was added directly into the culture medium, and the cells were incubated for
Dexamethasone was used to see the effect of pure glu-
ducted the formation of promoter activity.
To see the effects of the coexpression of various transcription factors on
the liver in vivo was examined by quantitative real-time PCR analysis. C57/BL6 mice
mouse PFK2/FBP2 mRNA (Applied Biosystems), and those
was harvested 24–48 h after the end of transfection, followed by the
cells were harvested 24–48 h after the end of transfection, followed by the
LXRE in vivo. In brief, HuH7 cells transfected with LXRα/RXRα expression plasmids were homogenized by a Dounce homogenizer and centrifuged, and the shared chromatin in the supernatant was incubated with protein G-coated magnetic beads, protease inhibitor cocktail, and anti-LXRα antibody (Perseus Proteomics) for 4 h at 4°C. The complex then was washed twice, treated with the reverse cross-liking buffer, and then incubated with protease K for 1 h at 37°C. Finally, the reaction solution was applied for PCR. The primer sets used are shown in Fig. 7A. Primer sets for negative control also were used following the manufacturer’s instructions.

Insulin and glucose assays. Blood glucose was measured by the glucose oxidase method. Plasma insulin was measured by the mouse insulin enzyme-linked immunosorbent assay kit (Morinaga Institute of Biological Science, Tokyo, Japan).

Statistical analysis. Samples in each group of the experiments were in triplicate or quadruplicate. All data were expressed as means ± SEM. When the statistical analyses were performed, data were compared by one-way ANOVA with the Fisher’s protected least significant difference test, and P values <0.05 were considered significant.

RESULTS

Endogenous expression of PFK1 and PFK2/FBP2 genes in HuH7 cells. There are four PFK2/FBP2 iso-enzymes in humans (PFKFB1, PFKFB2, PFKFB3, and PFKFB4) (4) and at least three PFK1 isoenzymes (PFKL, PFKM, and PFKP/PFKC) (17–19). Among them, PFKL and PFKFB1 are known to be expressed in the liver in vivo. Indeed, we found endogenous expression of PFKL and PFKFB1 mRNA in HuH7 cells analyzed by RT-PCR (Fig. 1B), indicating that this cell line is appropriate for the transcriptional regulation of the PFKFB1 isoform of the PFK2/FBP2 gene in vitro.

Effects of glucoregulatory hormones on the transcriptional activity of the PFK2/FBP2 gene. We first examined the effects of hormones related to glucose metabolism, such as insulin, glucagon/cAMP, and glucocorticoid, on the
FIG. 3. Effects of insulin/glucose-related transcription factors on the 5'-promoter activity of the PFK2/FBP2 gene. A: Coexpression experiment. HuH7 cells were transfected with the PFK2/FBP2-Luc and each test plasmid [SREBP1c (S), LXRα/β (Lα/β), and/or RXRα (Rα) and ChREBP (Ch) and/or Mlx expression plasmids] [reporter plasmid (μg): expression plasmid(s) (μg) = 1:1], and then the cells were cultured for 24 h. Each value is shown as a percentage of the corresponding control. *P < 0.05 vs. corresponding control [C (open bars); empty plasmid].

B: Time-course and dose-response experiments. HuH7 cells were transfected with PFK2/FBP2-Luc plasmid and LXRα/RXRα expression plasmids [reporter plasmid (μg): expression plasmid(s) (μg) = 1:1] and the cells were cultured for various time intervals (6–48 h) (time-course study) or for 48 h without or with TO-901317 (1 μmol/L) (dose-response experiment). *P < 0.05 vs. value at time zero [0 (open bars)] or corresponding control (C; empty plasmid). C: Combination experiment. HuH7 cells were transfected with PFK2/FBP2-Luc, LXRα/RXRα expression plasmids, and SREBP1c (S), LXRβ (Lβ), or ChREBP/Mlx (Ch) expression plasmid(s) [reporter plasmid (μg): expression plasmid(s) (μg) = 1:1], and then the cells were cultured for 48 h. *P < 0.05 vs. corresponding control [C (open bars); empty plasmid]. #P < 0.05 vs. LXRα/RXRα group (Lα). In all figures, hatched, dotted, or closed bars represent values of treated groups.
transcriptional activity of the PFK2/FBP2 gene. We found that insulin significantly stimulated the transcription of the PFK2/FBP2 gene in time- and dose-dependent manners (Fig. 2A). In contrast, forskolin/cAMP, a surrogate of glucagon, and dexamethasone showed significant inhibitory effects (Fig. 2B). Considering the fact that insulin is an anabolic/glycolytic hormone, whereas glucagon/cAMP is a gluconeogenic hormone, our results suggest that the regulation of the PFK2/FBP2 gene is similar to that of other glycolytic rather than gluconeogenic genes, at the transcriptional level.

Effects of the coexpression of insulin/glucose-related transcription factors on the transcriptional activity of the PFK2/FBP2 gene. Because the 5'-promoter activity of the PFK2/FBP2 gene is found to be regulated like that of other anabolic/glycolytic enzyme genes, transcription factors under the control of insulin/glucose, such as SREBP1c, LXRα/β, and ChREBP/Mlx, seem to be involved in its transcription. Therefore, we next tried to determine which transcriptional factor(s) is regulating the expression of the PFK2/FBP2 gene by coexpression experiments. The results showed that, among the factors examined, LXRα/RXRα potently (≥900% increase) stimulated the 5'-promoter activity of the PFK2/FBP2 gene (Fig. 3A). Other factors also had significant positive effects but much less (~1.5- to 2-fold increase) so than that of LXRα/RXRα. The effect of LXRα/RXRα coexpression was time dependent (Fig. 3B, left panel) and also dose dependent, which was further augmented by a specific LXR ligand, TO-901317 (TO; 1 μmol/L), or both for 24 h. Each value is shown as a percentage of the control [C (open bars)]. *P < 0.05 vs. control. #P < 0.05 vs. insulin alone. C: HuH7 cells were transfected with LXRα-Luc plasmid and insulin receptor expression plasmid [reporter plasmid (μg): expression plasmid(s) (μg) = 1:1] and then treated with vehicle or insulin (10 nmol/L) for 24 h. *P < 0.05 vs. control [C (open bars)]. In all figures, hatched, dotted, or closed bars represent values of treated groups.

FIG. 4. Effects of the LXR agonist/activator and insulin on the 5'-promoter activity of the PFK2/FBP2 gene. A: HuH7 cells were transfected with PFK2/FBP2-Luc and LXRα/RXRα expression plasmids or empty plasmid [reporter plasmid (μg): expression plasmid(s) (μg) = 1:1] and then treated with LXR ligand TO-901317 (1 μmol/L) for 24 h (left panel), or cultured with low (100 mg/dL) or high glucose (330 mg/dL) for 24 h (right panel). *P < 0.05 vs. corresponding control. B: HuH7 cells were transfected with PFK2/FBP2-Luc plasmid, insulin receptor expression plasmid, and LXRα/RXRα expression plasmids [reporter plasmid (μg): expression plasmid(s) (μg) = 1:1] and then treated with vehicle, insulin (Ins; 10 nmol/L), TO-901317 (TO; 1 μmol/L), or both for 24 h. Each value is shown as a percentage of the control [C (open bars)]. *P < 0.05 vs. control. #P < 0.05 vs. insulin alone. C: HuH7 cells were transfected with LXRα-Luc plasmid and insulin receptor expression plasmid [reporter plasmid (μg): expression plasmid (μg) = 1:1] and then treated with vehicle or insulin (10 nmol/L) for 24 h. *P < 0.05 vs. control [C (open bars)].
FIG. 5. Deletion/mutation analyses of the LXRα/RXRα activation of the PFK2/FBP2 gene. A: Deletion analysis. HuH7 cells were transfected with a plasmid containing one of the PFK2/FBP2 gene promoter deletion mutants (−1197, −698, −448, or −282 bp) and LXRα/RXRα expression plasmids [reporter plasmid (mg): expression plasmids (mg) = 1:1], and the cells were cultured for 48 h. Each value is shown as a percentage of the corresponding control (empty plasmid). *P < 0.05 vs. corresponding control. B: Site-directed mutagenesis analysis. The upper panel shows the nucleotide sequences of the proximal region of the human PFK2/FBP2 gene. Two putative LXR response elements are shown in the boxes. The middle panel shows the mutations introduced in either LXRE1 (upstream) or LXRE2 (downstream). The lower panel shows the effects of LXRE1/LXRE2 mutations on the LXRα/RXRα-induced PFK2/FBP2 gene transcription. HuH7 cells were transfected with a plasmid containing wild-type or one of the mutated PFK2/FBP2 gene promoters (LXRE1mut or LXRE2mut) and LXRα/RXRα expression plasmids [reporter plasmid (mg): expression plasmids (mg) = 1:1], and the cells were cultured for 48 h. Each value is shown as a percentage of the corresponding control (empty plasmid). *P < 0.05 vs. corresponding control. #P < 0.05 vs. wild-type PFK2/FBP2 (−282/+33 bp) promoter activity coexpressed with LXRα/RXRα. C: Heterologous construct analysis. HuH7 cells were transfected with the test
Effects of TO-901317, glucose, and insulin on the transcriptional activities of PFK2/FBP2 and LXRα genes. To confirm the involvement of LXRα/RXRα in the regulation of the PFK2/FBP2 gene, we next examined the effects of a synthetic LXRα ligand, TO-901317, and a putative endogenous LXRα activator, glucose (or its metabolite [s]) (20), on PFK2/FBP2 gene transcription. In naïve HuH7, treatment of the cells with high glucose (330 mg/dL) or TO-901317 had no significant effect on PFK2/FBP2 gene 5’-promoter activity. On the other hand, when LXRα/RXRα was coexpressed, mild but significant transcriptional induction was observed by either treatment (Fig. 4A). We then examined the role of insulin in LXRα/RXRα-mediated PFK2/FBP2 gene transcription. Under the condition where LXRα/RXRα was coexpressed, insulin as well as TO-901317 caused significant positive effects, and a further increase was observed when cells were treated with both insulin and TO-901317 (Fig. 4B). These results suggest that a factor(s) other than LXRα/RXRα also is involved in the positive effect of insulin. In addition, the transcriptional activity of the LXRα gene was significantly stimulated by insulin (Fig. 4C), as reported previously (21).

Deletion/mutation analyses of the LXRα/RXRα-dependent effect on the transcriptional activity of the PFK2/FBP2 gene. We next tried to identify the LXRE(s) in the PFK2/FBP2 gene 5’-promoter. We first performed deletion analysis. Our initial experiment showed that deletion up to −282 bp did not eliminate LXRα/RXRα responsiveness (Fig. 5A), suggesting that the LXRE seems to be located in the proximal portion of the PFK2/FBP2 gene promoter. We then analyzed this region more precisely using a site-directed mutagenesis technique. Within −282 bp of the promoter, we found two putative LXRE consensus sequences, LXRE1 and LXRE2 (Fig. 5B, upper panel). We introduced mutation in either or both of the elements (Fig. 5B, middle panel) and then examined the effect of LXRα/RXRα coexpression. We found that the mutation of LXRE1 did not affect the responsiveness, whereas the mutation of LXRE2 markedly diminished it, although a significant increase still remained (Fig. 5B, lower panel). In addition, we recognized a significant positive effect of LXRα/RXRα coexpression in a heterologous construct containing only LXRE2 (Fig. 5C). No effect was found in empty plasmid (TK-Luc alone) (data not shown). These results suggest that LXRE2 plays a significant role in the LXRα/RXRα-mediated transcriptional activation of the PFK2/FBP2 gene.

Binding of LXRα/RXRα on the LXRE2 of the PFK2/FBP2 gene by EMSA. We then tried to confirm the LXR binding of the LXRE2 element by EMSA. We found a clear single band, which was completely competed by an excess amount of unlabeled probe containing consensus LXRE but not by that with the mutated element (Fig. 6A, left panel). A clear supershifted band was observed when the proteins were pre-treated with anti-LXRα antibody (right panel).

Effects of fasting/refeeding on PFK2/FBP2 mRNA expression in the mouse liver. Finally, we performed an in vivo experiment to determine whether nutritional status indeed influences the expression level of PFK2/FBP2 plasmid containing only LXRE2 of the PFK2/FBP2 gene (~191~165 bp) fused with TK minimal promoter, and LXRα/RXRα expression plasmids or empty plasmid [reporter plasmid (μg): expression plasmids (μg) = 1:1]. The cells were then cultured for 48 h. *P < 0.05 vs. control (empty plasmid).
mRNA in the mouse liver by quantitative RT-PCR. We found that fasting/refeeding caused a significant increase in plasma insulin (Fig. 8A), whereas no difference was found in blood glucose levels (Fig. 8B). In this condition, RT-PCR analysis showed that PFK2/FBP2 mRNA was markedly increased in fasting/refeeding compared with fasting alone (Fig. 8C). These in vivo results are in accordance with our in vitro data, suggesting that PFK2/FBP2 gene transcription is regulated in a similar way as other anabolic/glycolytic enzyme genes rather than gluconeogenic enzyme genes.

**DISCUSSION**

PFK2/FBP2, a bifunctional enzyme involved in both glycolysis and gluconeogenesis, plays an important role in the regulation of glucose metabolism in the liver. In this study, we comprehensively examined the transcriptional regulation of the PFK2/FBP2 gene, using the HuH7 human hepatocyte-derived cell line in vitro and the mice liver tissue in vivo. We found that the promoter activity of the PFK2/FBP2 gene was stimulated by insulin and inhibited by forskolin/cAMP at the transcriptional level, suggesting that the PFK2/FBP2 gene is regulated in a similar way as other glycolytic enzyme genes rather than gluconeogenic enzyme genes (22–24). Furthermore, among the insulin/glucose-related transcription factors, we found that LXRα/RXRα is one of the key regulators of PFK2/FBP2 gene transcription. In addition, our in vivo experiment also showed that endogenous PFK2/FBP2 mRNA in the liver is induced by fasting/refeeding compared with fasting alone, in agreement with the previous report obtained in the rat liver estimated by Northern blot analysis (8).

Glycolysis/gluconeogenesis is known to be controlled not only by the regulation of enzyme activities but also by their expression levels. Regarding the PFK2/FBP2 gene, previous studies have shown that insulin, a representative anabolic/glycolytic hormone, increased the mRNA of the type PFK2/FBP2 gene in the adult rat hepatocyte in vitro (9), in the rat-derived FAO-1 hepatoma cells in vitro (10), and also in the rat liver in vivo (8). Because insulin and/or glucose and its metabolite(s) is known to play an important role in the regulation of glycolytic enzyme genes, we surveyed the role of the insulin/glucose-related regulatory factors as well. Indeed, coexpression of LXRα/β, and ChREBP/Mlx, and identified LXRα as one of the key regulatory factors in PFK2/FBP2 gene expression. LXRα (NR1H3) and LXRβ (NR1H2) belong to the nuclear receptor superfamily and are known to be involved in glucose and fatty acid synthesis as well as intracellular cholesterol metabolism (25–27). Insulin stimulates LXRα expression in hepatocytes (21), and LXRα is known to induce a variety of metabolism-related target genes directly or indirectly (27–30). To confirm that the involvement of LXRα on PFK2/FBP2 gene transcription is functional, we examined the effects of a specific LXR ligand, TO-901317, and found that in the presence of LXRα/RXRα, the ligand significantly increased the transcriptional activity of PFK2/FBP2 gene by 50–100%. A similar but weaker effect was observed when cells were treated with high glucose, a putative activator of LXRα (20). To further confirm that the PFK2/FBP2 gene is a direct target of LXRα, deletion/mutation analyses and an experiment using heterologous promoter (TK) construct were carried out, with the result that LXRα was identified as a cis-acting element for LXRα/RXRα. EMSAs and ChIP assays also provided convincing data supporting the direct binding of LXRα/RXRα on the element. Our data do not directly support the idea that LXRα is the predominant factor mediating the insulin stimulation of PFK2/FBP2 gene expression. However, considering the facts that insulin is known to be a potent inducer of LXRα (21), and that the current data show a marked stimulatory effect of LXRα/RXRα on PFK2/FBP2 gene promoter activity, we assume that LXRα is at least partly mediating the positive effect of insulin on PFK2/FBP2 gene transcription.

The present results suggest the possible role of other transcription factors as well. Indeed, coexpression of insulin/receptor-transcription factors, such as SREBP1c and LXRα, and the glucose-metabolite(s)-stimulated factor ChREBP/Mlx also caused a significant increase in the transcriptional activity of the PFK2/FBP2 gene, although the effects were much weaker than that of LXRα/RXRα.

**FIG. 7.** ChIP assay. A: The nucleotide sequences of the primers for PCR used in the assay. Primers recommended by the manufacturers’ instruction of the ChIP-IT Express chromatin immunoprecipitation kit was used as a negative control (see Research Design and Methods). B: HuH7 cells were transfected with LXRα/RXRα expression plasmids, and the cells were homogenized with Dounce-type homogenizer and then treated with anti-LXRα antibody. The protein-DNA complex was separated with protein G-coated beads, treated with protease K, and then applied for PCR amplification (for details, see Research Design and Methods).
Furthermore, simultaneous treatment of insulin and TO-901317 under the coexpression of LXRA/RXRα had a minimal but significant additive effect, suggesting that a factor(s) other than LXRA/RXRα is mediating the additional effect of insulin. The presence of different pathway(s) and/or element(s) also is suggested by the fact that a weaker but significant stimulatory effect of LXRα/RXRα still exists in the mutant promoter construct in which the confirmed LXR binding site (LXRE2) is deleted or mutated. Because no possible LXR binding site was found in the nucleotide sequence of the remaining promoter region, we assume that some unknown factor(s) induced by LXRα, possibly SREBP1c, is responsible for the remaining positive effect observed in the shortest construct (−282/+33 bp), because the expression of SREBP1c is partly dependent on LXRA/RXRα (29,30).

LXRα is expressed dominantly in the liver and regulates genes involved not only in sterol metabolism but also in fatty acid synthesis, such as acetyl CoA carboxylase and fatty acid synthase via LXREs located in the promoter of each gene (24,28,31). It generally is recognized that the glycolytic pathway is a part of the lipogenic pathway, and, indeed, under the control of PFK2/FBP2, PFK1 produces dihydroxyacetone phosphate, which is a precursor of glycerol-3-phosphate, a basic component of triglyceride. In this sense, it is not surprising that LXRα regulates gene expression related to not only fatty acid synthesis but also to glycolysis. To our knowledge, however, this is the first work showing that a gene (PFK2/FBP2) belonging to the Embden-Meyerhof pathway also is a direct target of LXRα.

In contrast to insulin, the glucagon/AMP pathway is known to have positive and negative effects on gluconeogenic and glycolytic enzyme gene expression, respectively (32), and, indeed, in this study, we found an inhibitory effect of forskolin on PFK2/FBP2 gene transcription. On the other hand, the effect of glucocorticoid is complex because the hormone facilitates gluconeogenesis during starvation, whereas it exhibits lipogenic effects in the anabolic condition. Regarding the effect of glucocorticoid on the PFK2/FBP2 gene, previous studies show conflicting results: dexamethasone decreased PFK2/FBP2 mRNA in adult rat hepatocytes (9), whereas opposite effects were observed in rat hepatoma-derived FAO and FTO-2B cells (10,11). The human PFK2/FBP2 gene has no clear glucocorticoid response element(s) in the promoter region examined in this study, and we found inhibitory rather than stimulatory effects. Additional studies using human primary hepatocyte cell culture are necessary to clarify the issue.

Finally, from the clinical standpoint, activation of LXRα is assumed to have a beneficial effect on glucose and cholesterol metabolism but at the same time can potentially facilitate fatty acid and triglyceride synthesis by inducing lipogenic genes, such as acetyl CoA carboxylase, fatty acid synthase, and PFK2/FBP2. Indeed, previous animal experiments showed that administration of the LXR ligand, TO-901317, improved diabetes but caused severe fatty liver and obesity (33,34). In contrast, selective inhibition of PFK2 causes decreased PFK1 activity, which decreases adipogenesis, as shown in PFK1-M knockout mice (19), but causes glycosgenesis and diabetes, as observed in PFK1-M-deficient humans (18). However, moderate inhibition of both PFK2 and FBP2 activities using LXR inhibitor may possibly be beneficial, because it will suppress both adipogenesis and gluconeogenesis without complete suppression of the mainstream glycolytic pathway. In this context, pharmacological inhibitors of LXRα or PFK2/FBP2 might be a promising therapeutic tool for the prevention of obesity and diabetes in the future.

ACKNOWLEDGMENTS
This work was supported in part by the Kochi University President’s Discretionary Grant, and Grants-in-Aid for Scientific Research (Research on Hypothalamo-Hypophyseal Disorders) from the Ministry of Health, Labor, and Welfare of Japan.

No potential conflicts of interest relevant to this article were reported.
L.-F.Z. performed research, analyzed the data, wrote the manuscript, and contributed to the discussion. Y.I. designed and performed research, analyzed the data, contributed to the discussion, and reviewed and edited the manuscript. M.N., T.T., M.T., M.O., S.N., K.H., and K.M. helped perform research and contributed to the discussion. M.K. performed research. S.F. and Y.T. reviewed the manuscript. Y.I. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Ms. Reiko Matsumoto (Department of Endocrinology, Metabolism, and Nephrology, Kochi Medical School, Kochi University) for her excellent technical support.

REFERENCES